دورية أكاديمية

PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

التفاصيل البيبلوغرافية
العنوان: PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
المؤلفون: Im, Seock-Ah, Xu, Binghe, Kim, Sung-Bae, Chung, Wei-Pang, Park, Yeon Hee, Kim, Min-Hwan, Tseng, Ling-Ming, Chung, Chi-Feng, Huang, Chiun-Sheng, Kim, Jee Hyun, Yan Chiu, Joanne Wing, Yamashita, Toshinari, Li, Wei, Lee, Caleb, Nishijima, Soichiro, Hamada, Kyohei, Nishiyama, Yuji, Sugihara, Masahiro, Cortés, Javier, Iwata, Hiroji
المصدر: In Annals of Oncology July 2022 33 Supplement 6:S464-S465
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2022.05.064